Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.